Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 29, 2026, 1:28 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 378 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: influenza virus infection Clear all
Completed No phase listed Observational Accepts healthy volunteers

Home Testing of Respiratory Illness

NCT04245800
View directory record Official record
Conditions
Influenza -Like Illness, Influenza A, Influenza Type B, Respiratory Viral Infection, Respiratory Tract Infections
Interventions
Not listed
Lead sponsor
Evidation Health
Industry
Eligibility
18 Years and older
Enrollment
5,233 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
San Mateo, California
Source: ClinicalTrials.gov public record
Updated Jul 21, 2020 · Synced Sep 29, 2026, 1:28 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Safety and Immunogenicity Among Healthy Children Receiving Fluzone® Influenza Virus Vaccine (2012-2013 Formulation)

NCT01691326
View directory record Official record
Conditions
Influenza
Interventions
Fluzone®: Influenza Virus Vaccine, No Preservative: Pediatric Dose, Fluzone®; Influenza Virus Vaccine, No Preservative
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
6 Months to 8 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
2
States / cities
Bardstown, Kentucky • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Apr 15, 2014 · Synced Sep 29, 2026, 1:28 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Study of Fluzone® Quadrivalent, Fluzone® Intradermal, and Fluzone® High-Dose Influenza Virus Vaccines in Adults

NCT01946438
View directory record Official record
Conditions
Influenza
Interventions
Fluzone® Quadrivalent, Influenza Virus Vaccine (2013-2014 formulation),, Fluzone® Intradermal, Influenza Virus Vaccine (2013-2014 formulation),, Fluzone® High-Dose, Influenza Virus Vaccine (2013-2014 formulation)
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
18 Years and older
Enrollment
208 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
4
States / cities
Santa Rosa, California • Council Bluffs, Iowa • Metairie, Louisiana + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 24, 2014 · Synced Sep 29, 2026, 1:28 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety and Immunogenicity of a Live Attenuated H7N9 Influenza Virus Vaccine in Healthy Adults

NCT01995695
View directory record Official record
Conditions
Influenza A Virus, H7N9 Subtype
Interventions
Live attenuated H7N9 A/Anhui/13 ca influenza virus vaccine, Inactivated subvirion H7N9 influenza vaccine
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 49 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2013
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Jul 26, 2016 · Synced Sep 29, 2026, 1:28 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Cellular and Humoral Immune Response to Primary and Secondary Immunization With Subvirion H5N1 Vaccines

NCT01086566
View directory record Official record
Conditions
Influenza
Interventions
Influenza Virus Vaccine, Monovalent A/H5N1 A/Indonesia/05/2005
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 64 Years
Enrollment
95 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2012
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Dec 31, 2015 · Synced Sep 29, 2026, 1:28 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

T-cell Response-Flu Risk in Older Adults

NCT00138398
View directory record Official record
Conditions
Influenza
Interventions
Commercial TriValent Split Influenza Virus
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
20 Years to 99 Years
Enrollment
850 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2005
U.S. locations
1
States / cities
Farmington, Connecticut
Source: ClinicalTrials.gov public record
Updated Feb 14, 2019 · Synced Sep 29, 2026, 1:28 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Atopic Dermatitis Research Network (ADRN) Influenza Vaccine Pilot

NCT01518478
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Fluzone® Intradermal (Sanofi Pasteur Inc.)
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 64 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Feb 28, 2017 · Synced Sep 29, 2026, 1:28 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Cigarette Smoke and Susceptibility to Influenza Infection

NCT00448617
View directory record Official record
Conditions
Healthy
Interventions
Not listed
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 35 Years
Enrollment
138 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2011
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated May 28, 2015 · Synced Sep 29, 2026, 1:28 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Half-Dose Flu Vaccine Study in Healthy Adults

NCT00006146
View directory record Official record
Conditions
Influenza
Interventions
Approved influenza virus vaccine.
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 49 Years
Enrollment
840 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2000
U.S. locations
6
States / cities
Torrance, California • College Park, Maryland • St Louis, Missouri + 3 more
Source: ClinicalTrials.gov public record
Updated Aug 26, 2010 · Synced Sep 29, 2026, 1:28 AM EDT
Completed No phase listed Observational

Clinical Performance Study of the Ultra Influenza A&B Test Using Nasal Swabs for Identifying Subjects Who Are Infected With the Influenza Virus Strain Type A or Type B

NCT01753531
View directory record Official record
Conditions
Influenza, Human
Interventions
Flu Symptoms
Device
Lead sponsor
Sekisui Diagnostics, LLC
Industry
Eligibility
3 Months and older
Enrollment
677 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
3
States / cities
Winston-Salem, North Carolina • Charleston, South Carolina • New Braunfels, Texas
Source: ClinicalTrials.gov public record
Updated Jun 23, 2013 · Synced Sep 29, 2026, 1:28 AM EDT
Terminated Phase 4 Interventional Accepts healthy volunteers

Th1 Response to Influenza: Aging and Vaccine Efficacy

NCT00396305
View directory record Official record
Conditions
Influenza
Interventions
Placebo, Trivalent Inactivated Influenza
Drug · Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
21 Years and older
Enrollment
41 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2008
U.S. locations
1
States / cities
Norfolk, Virginia
Source: ClinicalTrials.gov public record
Updated Aug 26, 2010 · Synced Sep 29, 2026, 1:28 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Effects of Tobacco Products on Live Attenuated Influenza Virus (LAIV) Infections in Human Volunteers

NCT02019745
View directory record Official record
Conditions
Influenza, Human, Smoking, Respiratory Tract Infections, Habits
Interventions
LAIV
Biological
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 45 Years
Enrollment
62 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2016
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 3, 2018 · Synced Sep 29, 2026, 1:28 AM EDT
Completed Phase 1 Interventional

Safety and Dose Study of Peramivir for Influenza Treatment

NCT00297050
View directory record Official record
Conditions
Influenza
Interventions
Peramivir
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 50 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 1, 2017 · Synced Sep 29, 2026, 1:28 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Immunogenicity, Safety of GSKs Tdap Vaccine Boostrix When Coadministered With GSKs Influenza Vaccine Fluarix in Adults

NCT00385255
View directory record Official record
Conditions
Acellular Pertussis, Diphtheria, Tetanus
Interventions
Fluarix®, Boostrix®
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
19 Years and older
Enrollment
1,726 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2007
U.S. locations
12
States / cities
Huntsville, Alabama • Chandler, Arizona • Mesa, Arizona + 8 more
Source: ClinicalTrials.gov public record
Updated Jun 9, 2019 · Synced Sep 29, 2026, 1:28 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Safety and Immunogenicity of a Live-attenuated Universal Flu Vaccine Followed by an Inactivated Universal Flu Vaccine

NCT03300050
View directory record Official record
Conditions
Influenza, Vaccine
Interventions
cH8/1N1 LAIV, AS03-adjuvanted cH5/1N1 IIV, cH5/1N1 IIV, AS03-adjuvanted cH8/1N1 IIV, Normal saline, Phosphate buffered saline (PBS)
Biological
Lead sponsor
PATH
Other
Eligibility
18 Years to 39 Years
Enrollment
65 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
2
States / cities
Durham, North Carolina • Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 20, 2021 · Synced Sep 29, 2026, 1:28 AM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Safety and Immunogenicity Testing of Influenza Vaccine in Healthy Children 2 Months and 6 Months of Age

NCT00858468
View directory record Official record
Conditions
Influenza
Interventions
Influenza virus vaccine (2004-2005 Formulation)
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
2 Months to 9 Months
Enrollment
394 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2006
U.S. locations
8
States / cities
Little Rock, Arkansas • Marietta, Georgia • Durham, North Carolina + 5 more
Source: ClinicalTrials.gov public record
Updated Apr 13, 2016 · Synced Sep 29, 2026, 1:28 AM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers

Study of a Combination Vaccine Comprised of Different Recombinant Spike Antigen Levels of a Matrix-M Adjuvanted Recombinant COVID-19 Vaccine and Recombinant Influenza Vaccine in Adult Participants 50 Years of Age and Older

NCT06695130
View directory record Official record
Conditions
COVID-19 Immunization, Influenza Immunization
Interventions
RIV (recombinant influenza vaccine), rC19 (dose 1), RIV + rC19 (dose 1), RIV + rC19 (dose 2), RIV + rC19 (dose 3), RIV + rC19 (dose 4), Placebo (0.9% NaCl)
Biological · Other
Lead sponsor
Sanofi
Industry
Eligibility
50 Years and older
Enrollment
980 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
12
States / cities
Phoenix, Arizona • Cerritos, California • Vista, California + 9 more
Source: ClinicalTrials.gov public record
Updated May 4, 2026 · Synced Sep 29, 2026, 1:28 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Post-Marketing Safety Study of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) mRNA-1273 COVID-19 Vaccine in the United States

NCT04958954
View directory record Official record
Conditions
SARS-CoV-2
Interventions
Not listed
Lead sponsor
ModernaTX, Inc.
Industry
Eligibility
Not listed
Enrollment
50,000,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 16, 2023 · Synced Sep 29, 2026, 1:28 AM EDT
Active, not recruiting Not applicable Interventional

Comparison of Nasopharyngeal Swab v. Nasopharyngeal Saline Wash or Saliva Collection in Testing for Respiratory Viruses

NCT05864118
View directory record Official record
Conditions
Respiratory Tract Infections
Interventions
Respiratory pathogen panel PCR test, COVID-19 antibody test
Diagnostic Test
Lead sponsor
University of Nebraska
Other
Eligibility
19 Years and older
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Apr 16, 2026 · Synced Sep 29, 2026, 1:28 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Trial to Describe the Safety and Immunogenicity of Fluzone®

NCT00524940
View directory record Official record
Conditions
Influenza
Interventions
Inactivated, Split-Virion Influenza Virus
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
18 Years and older
Enrollment
124 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007
U.S. locations
1
States / cities
Norfolk, Virginia
Source: ClinicalTrials.gov public record
Updated Apr 13, 2016 · Synced Sep 29, 2026, 1:28 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Flublok or Fluzone With Advax-CpG55.2 or AF03

NCT03945825
View directory record Official record
Conditions
Influenza, Influenza Immunisation
Interventions
AF03, Delta Inulin-CpG55.2, Influenza Virus Quadrivalent Inactivated Vaccine, Quadrivalent Recombinant Seasonal Influenza Vaccine
Drug · Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 45 Years
Enrollment
241 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
8
States / cities
Atlanta, Georgia • Iowa City, Iowa • Baltimore, Maryland + 5 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2025 · Synced Sep 29, 2026, 1:28 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Experimental AD4-H5-VTN Vaccine in Healthy Volunteers

NCT01443936
View directory record Official record
Conditions
H5N1 Influenza
Interventions
Ad4-H5-VTN vaccination-tonsillar route, Ad4-H5-vaccination-oral route
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 49 Years
Enrollment
96 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2019
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 15, 2019 · Synced Sep 29, 2026, 1:28 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Evaluate the Safety and Immunogenicity of a Seasonal Influenza VLP Vaccine (Recombinant) in Healthy Adults

NCT00754455
View directory record Official record
Conditions
Influenza
Interventions
Influenza VLP Vaccine (recombinant), Placebo
Biological
Lead sponsor
Novavax
Industry
Eligibility
18 Years to 49 Years
Enrollment
317 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
4
States / cities
Pembroke Pines, Florida • Kansas City, Missouri • Warwick, Rhode Island + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 17, 2013 · Synced Sep 29, 2026, 1:28 AM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers

A Study of mRNA-1018 Pandemic Influenza Candidate Vaccines in Healthy Adults

NCT05972174
View directory record Official record
Conditions
Influenza
Interventions
mRNA-1018 for H5N8, mRNA-1018 for H7N9, mRNA-1018 for H5 Only, mRNA-1018 for H7 Only, mRNA-1018 for H5 Only-CG
Biological
Lead sponsor
ModernaTX, Inc.
Industry
Eligibility
18 Years and older
Enrollment
1,504 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
9
States / cities
Hollywood, Florida • Savannah, Georgia • Lenexa, Kansas + 6 more
Source: ClinicalTrials.gov public record
Updated Jul 15, 2025 · Synced Sep 29, 2026, 1:28 AM EDT